AbbVie: ITTM and AbbVie to collaborate on Disease Map for Alzheimer’s
Information Technology for Translational Medicine, S.A. (ITTM S.A.) announced today that it has signed a two-year agreement with AbbVie Germany to develop and build a comprehensive and interactive up-to-date knowledge map for Alzheimer’s Disease. The disease map will be built using MINERVA, a platform for visualization and curation of molecular interaction networks developed by Luxembourg Centre of Systems Biomedicine of the University of Luxembourg.
Alzheimer’s Disease is the most common cause of dementia among older adults and is an irreversible, progressive brain disorder. Research is focused on elucidating complex brain changes involved in the onset and progression of Alzheimer’s disease. Despite the efforts there is still no cure or prevention available. Comprehensive and interactive disease maps facilitate the understanding of pathophysiology, the identification of potential therapeutic intervention points and hypothesis generation and evaluation.
“Our goal is to provide flexible solutions and services that fit the requirements of our partners. Providing an interactive solution supporting curation, annotation and visualization of molecular interaction networks together with pre-clinical and clinical data enables the exploration and interpretation of data in the right context.” says Dr. Andreas Kremer, Managing Director of ITTM S.A.
“We see the disease map of Alzheimer’s Disease as a great opportunity to create a central knowledge base of relevant pathway information. With the interactive integration of experimental results it will contribute to data interpretation. The ITTM has proven to be an excellent partner for disease map development and customization.” says Dr. Janina Ried, Computational Biologist in Neuroscience Discovery, AbbVie Germany. Dr. Alfred Hahn, Head of Neuroscience Discovery, AbbVie Germany adds “I believe that the focused, de novo pathway curation provided by the ITTM will support generation of new research hypothesis for experimental testing.“
Read full press release here